The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

Carlos Doti has moved countries and changed jobs, but one thing hasn’t changed. Making an impact on patient care has always ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Despite substantial variability in the presented data and no well-controlled trial, the FDA advisory committee voted in favor ...

Turnstone is shifting resources to focus on clinical advancement of its selected tumor-infiltrating lymphocyte therapy as ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

The rejection is related to the timing of the FDA’s reinspection of Zealand’s third-party manufacturer, which previously had ...

Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the ...

Tim Hunt, CEO of the Alliance for Regenerative Medicine, said Monday at the 2024 Cell & Gene Meeting on the Mesa that ...